Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, Rennes, France; University of Rennes, National Institute of Health and Medical Research, Center of Clinical Investigation, Research Institute for Environmental and Occupational Health, University Hospital Federation Survival Optimization in Organ Transplantation, Univ Rennes, Rennes, France.
Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, Rennes, France.
Anesthesiology. 2024 Jun 1;140(6):1153-1164. doi: 10.1097/ALN.0000000000004920.
Unfractionated heparin, administered during venoarterial extracorporeal membrane oxygenation to prevent thromboembolic events, largely depends on plasma antithrombin for its antithrombotic effects. Decreased heparin responsiveness seems frequent on extracorporeal membrane oxygenation; however, its association with acquired antithrombin deficiency is poorly understood. The objective of this study was to describe longitudinal changes in plasma antithrombin levels during extracorporeal membrane oxygenation support and evaluate the association between antithrombin levels and heparin responsiveness. The hypothesis was that extracorporeal membrane oxygenation support would be associated with acquired antithrombin deficiency and related decreased heparin responsiveness.
Adults receiving venoarterial extracorporeal membrane oxygenation were prospectively included. All patients received continuous intravenous unfractionated heparin using a standardized protocol (target anti-Xa 0.3 to 0.5 IU/ml). For each patient, arterial blood was withdrawn into citrate-containing tubes at 11 time points (from hour 0 up to day 7). Anti-Xa (without dextran or antithrombin added) and antithrombin levels were measured. The primary outcome was the antithrombin plasma level. In the absence of consensus, antithrombin deficiency was defined as a time-weighted average of antithrombin less than or equal to 70%. Data regarding clinical management and heparin dosage were collected.
Fifty patients, including 42% postcardiotomy, were included between April 2020 and May 2021, with a total of 447 samples. Median extracorporeal membrane oxygenation duration was 7 (interquartile range, 4 to 12) days. Median antithrombin level was 48% (37 to 60%) at baseline. Antithrombin levels significantly increased throughout the follow-up. Time-weighted average of antithrombin levels was 63% (57 to 73%) and was less than or equal to 70% in 32 (64%) of patients. Overall, 45 (90%) patients had at least one antithrombin value less than 70%, and 35 (70%) had at least one antithrombin value less than 50%. Antithrombin levels were not significantly associated with heparin responsiveness evaluated by anti-Xa assay or heparin dosage.
Venoarterial extracorporeal membrane oxygenation support was associated with a moderate acquired antithrombin deficiency, mainly during the first 72 h, that did not correlate with heparin responsiveness.
在进行静脉-动脉体外膜肺氧合(VA-ECMO)时,使用未分馏肝素来预防血栓栓塞事件,其抗血栓作用在很大程度上依赖于血浆抗凝血酶。VA-ECMO 期间肝素反应性降低似乎很常见;然而,其与获得性抗凝血酶缺乏的关联尚未被很好地理解。本研究的目的是描述在 ECMO 支持期间血浆抗凝血酶水平的纵向变化,并评估抗凝血酶水平与肝素反应性之间的关系。假设 ECMO 支持与获得性抗凝血酶缺乏和相关肝素反应性降低有关。
前瞻性纳入接受静脉-动脉 ECMO 的成年人。所有患者均按照标准化方案接受连续静脉注射未分馏肝素(目标抗 Xa 为 0.3 至 0.5IU/ml)。对于每个患者,在 11 个时间点(从 0 小时到第 7 天)从含柠檬酸盐的管中抽取动脉血。测量抗 Xa(未添加葡聚糖或抗凝血酶)和抗凝血酶水平。主要结局是抗凝血酶的血浆水平。在没有共识的情况下,抗凝血酶缺乏被定义为抗凝血酶的时间加权平均值小于或等于 70%。收集有关临床管理和肝素剂量的数据。
2020 年 4 月至 2021 年 5 月期间共纳入 50 例患者,包括 42%的心脏手术后患者,共采集了 447 份样本。ECMO 持续时间中位数为 7 天(四分位间距 4 至 12 天)。基线时抗凝血酶水平中位数为 48%(37%至 60%)。整个随访过程中抗凝血酶水平显著升高。抗凝血酶的时间加权平均值为 63%(57%至 73%),32 例(64%)患者的抗凝血酶水平小于或等于 70%。总体而言,45 例(90%)患者至少有一次抗凝血酶值小于 70%,35 例(70%)患者至少有一次抗凝血酶值小于 50%。抗凝血酶水平与通过抗 Xa 测定或肝素剂量评估的肝素反应性无显著相关性。
静脉-动脉 ECMO 支持与中度获得性抗凝血酶缺乏有关,主要发生在最初的 72 小时内,与肝素反应性无关。